HealthEquity reported a 21% increase in revenue to $300.4 million, with net income at $5.7 million and non-GAAP net income at $69.4 million. The company saw growth in HSAs to 9.5 million and total accounts to 16.5 million. They repurchased 0.7 million shares for $60 million and raised fiscal year 2025 guidance.
Revenue increased by 21% to $300.4 million compared to Q3 FY24.
HSAs grew to 9.5 million, a 15% increase year-over-year.
Total accounts, including HSAs and CDBs, reached 16.5 million, up 8% from Q3 FY24.
The company repurchased 0.7 million shares of its common stock for $60.0 million.
For the fiscal year ending January 31, 2025, HealthEquity anticipates revenue between $1.185 billion and $1.195 billion, net income of $88 million to $96 million ($0.99 to $1.08 per diluted share), non-GAAP net income of $274 million to $281 million ($3.08 to $3.16 per diluted share), and Adjusted EBITDA of $470 million to $480 million. For fiscal year 2026, they expect revenue of approximately $1.275 billion to $1.295 billion and Adjusted EBITDA of approximately 41.5% to 42.5% of revenue.
Visualization of income flow from segment revenue to net income